Replacement: Investment update - Paraytec
This announcement replaces RNS Number 0231Z released by Truetide plc at 07.00 a.m. on 15 October 2026. The original RNS incorrectly stated that ‘breath samples’ had been collected and used in the proof-of-concept project work. In fact, no human samples have been taken or processed and therefore the text below has been corrected to refer to the use of ‘simulated air samples’. As a result, the following statements were premature and have also been deleted from the text:
- Reference to the baseline characterisation of particle number, size distribution and background fluorescence confirming compatibility with CX300 analysis
- Reference to ‘stable’ from the statement: ‘demonstration of stable, repeatable signals on CX300, with negligible carryover between samples
- Details of the specific EV sub-populations which may be detected as part of Phase 3.
All other details remain unchanged and the full amended text is shown below with amendments in bold.
Truetide plc
("Truetide" or the "Company")
Investment Update – Paraytec: Successful Completion of Phase 2, Breath-Derived EV Programme with VosBio
Truetide plc (AIM: TRUE) is pleased to provide an update on its 100%-owned investee company, Paraytec Limited ("Paraytec"), and its work with VosBio Inc. ("VosBio"). As announced on 25 June 2026, Paraytec and VosBio agreed heads of terms (“HoTs”) for a proposed research and development collaboration to evaluate the feasibility of combining VosBio's breath-collection technology with Paraytec's CX300 platform in the field of early, non-invasive lung cancer detection.
Both parties agreed to commence the initial ‘proof-of-concept’ groundwork under the existing HoTs and the Company is pleased to report that Phase 2 in the proposed six-month development programme has been completed successfully.
Phase 2 — Breath EV Recovery and Baseline Characterisation
Phase 2 was focused on demonstrating that simulated air samples collected using the VosBio Universal Breath Collector, a device for the rapid, non-invasive capture of exhaled breath condensate (“EBC”), contain recoverable EV-like particles and that prepared samples can be measured consistently on the CX300 platform. Key outcomes achieved during Phase 2 include:
• successful recovery of EV-like particles from simulated air samples collected using the VosBio device;
• selection of a practical sample-preparation method for reproducible results on the CX300;
• demonstration of repeatable signals on CX300, with negligible carryover between samples.
These results demonstrate the technical feasibility of the combined VosBio-Paraytec workflow and establish the foundation for Phase 3. Phase 3 will focus on developing fluorescent antibody labelling to identify specific EV sub-populations associated with the lung microenvironment.
No human samples have been taken or processed. Successful completion of Phase 2 is an important technical de-risking step for the programme. A breath-based EV assay could potentially support lung cancer screening or triage, patient stratification, disease monitoring and treatment-response studies by providing a non-invasive and repeatable route for sampling lung-proximal biological material.
Next Steps
Phase 3, which focuses on the development and optimisation of an antibody panel for identifying lung-relevant EV sub-populations, is now underway. The parties are working to finalise the definitive collaboration agreement and the Company will update shareholders on its completion and of subsequent development phases. If a follow-on clinical validation plan is agreed, will also provide a further update at that time.
Trevor Brown, CEO of Truetide plc, commented:
“The collaboration and the feasibility programme funded by VosBio are progressing well. These results demonstrate the potential for the CX300 platform to be applied in an area of significant unmet clinical need in early cancer screening. We will continue to update shareholders as the programme progresses.”
For further information:
|
|
|
|
Truetide plc |
Tel: 01738 587555 |
|
Trevor Brown, Chief Executive Officer Viv Hallam, Executive Director |
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
James Reeve / Ashur Joseph |
|
|
|
|
|
AlbR Limited (Joint Broker) |
Tel: 020 7469 0936 |
|
Duncan Vasey / Lucy Williams |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE